faa tirzepatide FDA confirms shortage is still over, gives compounders a grace period HIGH ON HEALTH: Medical Matters

A careful evaluation with a qualified provider remains the most important step before beginning any peptide regimen.

The FDA states that available data is insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other maternal or fetal outcomes. What we do have comes primarily from animal studies, and those findings raised concerns

The study, which was conducted over a 68-week period, also required both groups those on the medication and those given the placebo to receive nutrition and physical activity counseling

GLP-1 patches vs GLP-1 injectables Efficacy: Will patches work as well as injections

Women with pre-existing PCOS or other reproductive conditions may benefit from more frequent monitoring